Autoimmune Hepatitis: 2019 Update

Area of Science:

• Hepatology
• Immunology
• Internal Medicine

Background:

• Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease with increasing global prevalence.
• Diagnosis relies on clinical findings, autoantibodies, elevated IgG, and histology, as no specific biomarker exists.
• Current treatment involves corticosteroids and azathioprine, with second-line options for non-responders or intolerant patients.

Purpose of the Study:

• To review the clinical diagnosis, treatment, and outcomes of autoimmune hepatitis.
• To highlight challenges in diagnosing acute-onset AIH and unmet needs in patient care.
• To discuss the potential for novel, corticosteroid-free treatment regimens.

Main Methods:

• Review of epidemiological trends and diagnostic criteria for AIH.
• Analysis of current treatment strategies, including first-line and second-line therapies.
• Discussion of long-term outcomes and challenges in disease management.

Main Results:

• AIH diagnosis requires a combination of clinical, serological, and histological evidence.
• Standard treatment with corticosteroids and azathioprine yields good outcomes but often requires lifelong maintenance.
• Acute-onset AIH presents diagnostic challenges, particularly when autoantibodies or elevated IgG are absent.

Conclusions:

• Effective management of AIH involves timely diagnosis and sustained immunosuppression.
• Relapse is common upon treatment cessation, necessitating long-term therapy for many patients.
• Future research should focus on earlier diagnostic methods, improved clinical guidelines, and novel corticosteroid-free treatments to enhance patient quality of life.